Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 161

1.

Nuclear PRAS40 couples the Akt/mTORC1 signaling axis to the RPL11-HDM2-p53 nucleolar stress response pathway.

Havel JJ, Li Z, Cheng D, Peng J, Fu H.

Oncogene. 2015 Mar 19;34(12):1487-98. doi: 10.1038/onc.2014.91. Epub 2014 Apr 7.

2.
3.

mTOR inhibitors blunt the p53 response to nucleolar stress by regulating RPL11 and MDM2 levels.

Goudarzi KM, Nistér M, Lindström MS.

Cancer Biol Ther. 2014;15(11):1499-514. doi: 10.4161/15384047.2014.955743.

4.

[Research progress in PRAS40].

Chen G, Zhu G, Zhang X.

Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2018 Jun 28;43(6):685-690. doi: 10.11817/j.issn.1672-7347.2018.06.017. Chinese.

5.

Pathological hypertrophy amelioration by PRAS40-mediated inhibition of mTORC1.

Völkers M, Toko H, Doroudgar S, Din S, Quijada P, Joyo AY, Ornelas L, Joyo E, Thuerauf DJ, Konstandin MH, Gude N, Glembotski CC, Sussman MA.

Proc Natl Acad Sci U S A. 2013 Jul 30;110(31):12661-6. doi: 10.1073/pnas.1301455110. Epub 2013 Jul 10.

6.

RhoA modulates signaling through the mechanistic target of rapamycin complex 1 (mTORC1) in mammalian cells.

Gordon BS, Kazi AA, Coleman CS, Dennis MD, Chau V, Jefferson LS, Kimball SR.

Cell Signal. 2014 Mar;26(3):461-7. doi: 10.1016/j.cellsig.2013.11.035. Epub 2013 Dec 3.

7.

The mechanism of insulin-stimulated 4E-BP protein binding to mammalian target of rapamycin (mTOR) complex 1 and its contribution to mTOR complex 1 signaling.

Rapley J, Oshiro N, Ortiz-Vega S, Avruch J.

J Biol Chem. 2011 Nov 4;286(44):38043-53. doi: 10.1074/jbc.M111.245449. Epub 2011 Sep 13.

8.

Akt-dependent activation of mTORC1 complex involves phosphorylation of mTOR (mammalian target of rapamycin) by IκB kinase α (IKKα).

Dan HC, Ebbs A, Pasparakis M, Van Dyke T, Basseres DS, Baldwin AS.

J Biol Chem. 2014 Sep 5;289(36):25227-40. doi: 10.1074/jbc.M114.554881. Epub 2014 Jul 2.

9.

p53/TAp63 and AKT regulate mammalian target of rapamycin complex 1 (mTORC1) signaling through two independent parallel pathways in the presence of DNA damage.

Cam M, Bid HK, Xiao L, Zambetti GP, Houghton PJ, Cam H.

J Biol Chem. 2014 Feb 14;289(7):4083-94. doi: 10.1074/jbc.M113.530303. Epub 2013 Dec 23.

10.

Proline-rich Akt substrate of 40kDa (PRAS40): a novel downstream target of PI3k/Akt signaling pathway.

Wang H, Zhang Q, Wen Q, Zheng Y, Lazarovici P, Jiang H, Lin J, Zheng W.

Cell Signal. 2012 Jan;24(1):17-24. doi: 10.1016/j.cellsig.2011.08.010. Epub 2011 Aug 31. Review. Erratum in: Cell Signal. 2012 Nov;24(11):2226. Philip, Lazarovici [corrected to Lazarovici, Philip].

PMID:
21906675
11.

Over-expression of PRAS40 enhances insulin sensitivity in skeletal muscle.

Wiza C, Chadt A, Blumensatt M, Kanzleiter T, Herzfeld De Wiza D, Horrighs A, Mueller H, Nascimento EB, Schürmann A, Al-Hasani H, Ouwens DM.

Arch Physiol Biochem. 2014 May;120(2):64-72. doi: 10.3109/13813455.2014.894076. Epub 2014 Feb 27.

PMID:
24576065
12.

AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy.

Astle MV, Hannan KM, Ng PY, Lee RS, George AJ, Hsu AK, Haupt Y, Hannan RD, Pearson RB.

Oncogene. 2012 Apr 12;31(15):1949-62. doi: 10.1038/onc.2011.394. Epub 2011 Sep 12.

13.

Role of PRAS40 in Akt and mTOR signaling in health and disease.

Wiza C, Nascimento EB, Ouwens DM.

Am J Physiol Endocrinol Metab. 2012 Jun 15;302(12):E1453-60. doi: 10.1152/ajpendo.00660.2011. Epub 2012 Feb 21.

14.

Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation.

Wang L, Harris TE, Lawrence JC Jr.

J Biol Chem. 2008 Jun 6;283(23):15619-27. doi: 10.1074/jbc.M800723200. Epub 2008 Mar 27.

15.

PICT-1 is a key nucleolar sensor in DNA damage response signaling that regulates apoptosis through the RPL11-MDM2-p53 pathway.

Chen H, Han L, Tsai H, Wang Z, Wu Y, Duo Y, Cao W, Chen L, Tan Z, Xu N, Huang X, Zhuang J, Huang L.

Oncotarget. 2016 Dec 13;7(50):83241-83257. doi: 10.18632/oncotarget.13082.

16.

Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40.

Vander Haar E, Lee SI, Bandhakavi S, Griffin TJ, Kim DH.

Nat Cell Biol. 2007 Mar;9(3):316-23. Epub 2007 Feb 4.

PMID:
17277771
17.

Proline-rich AKT substrate of 40-kDa (PRAS40) in the pathophysiology of cancer.

Malla R, Ashby CR Jr, Narayanan NK, Narayanan B, Faridi JS, Tiwari AK.

Biochem Biophys Res Commun. 2015 Jul 31;463(3):161-6. doi: 10.1016/j.bbrc.2015.05.041. Epub 2015 May 20. Review.

PMID:
26003731
18.

PRAS40 is a target for mammalian target of rapamycin complex 1 and is required for signaling downstream of this complex.

Fonseca BD, Smith EM, Lee VH, MacKintosh C, Proud CG.

J Biol Chem. 2007 Aug 24;282(34):24514-24. Epub 2007 Jun 29.

19.

The proline-rich Akt substrate of 40 kDa (PRAS40) is a physiological substrate of mammalian target of rapamycin complex 1.

Oshiro N, Takahashi R, Yoshino K, Tanimura K, Nakashima A, Eguchi S, Miyamoto T, Hara K, Takehana K, Avruch J, Kikkawa U, Yonezawa K.

J Biol Chem. 2007 Jul 13;282(28):20329-39. Epub 2007 May 21.

20.

Overexpression of PRAS40(T246A) in the Proliferative Compartment Suppresses mTORC1 Signaling, Keratinocyte Migration, and Skin Tumor Development.

Rho O, Srivastava J, Cho J, DiGiovanni J.

J Invest Dermatol. 2016 Oct;136(10):2070-2079. doi: 10.1016/j.jid.2016.06.013. Epub 2016 Jun 24.

Supplemental Content

Support Center